Patient safety is, and will always remain, Lilly’s highest priority Eli Lilly and Company (India) commends the actions taken by the Haryana drug control authority in addressing counterfeit products falsely bearing the Mounjaro® (tirzepatide) brand name that were recently seized in Gurugram, Haryana. These seized counterfeit
Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda Eli Lilly and Company today announced plans to invest more than $1 Billion over the next several years into new contract manufacturing in India, expanding patients’ access to innovative
Hyderabad site will support innovation and strengthen digital capabilities across Lilly’s global operations. New centre creates opportunities for local talent and advances Hyderabad’s biotech ecosystem Eli Lilly and Company (India) today announced the opening of its new technology and innovation site in Hyderabad; a new
Participants using tirzepatide lost 22.8 kg and participants on semaglutide lost 15.0 kg SURMOUNT-5 compared tirzepatide, a dual GIP and GLP-1 receptor agonist, to semaglutide, a mono GLP-1 receptor agonist in adults living with obesity without diabetes Eli Lilly and Company (NYSE: LLY) today announced topline results
